HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Long-term prevention of the recurrence of auricular fibrillation using cibenzoline. Multicenter study apropos of 89 case reports].

Abstract
The aim of this study was to evaluate the long-term efficacy of cibenzoline in preventing recurrence of atrial fibrillation compared to a reference drug: quinidine arabo-galactane sulfate (QAGS). The two products were administered orally in a double blind multicentre trial to two different groups of patients (96 patients in all) in whom atrial fibrillation had been previously converted to sinus rhythm after having been present for at least 15 days and less than 18 months. The patients were either given four 65 mg gelules of cibenzoline (group I) or four 206 mg gelules of Longacor (group II) and were reviewed systematically after 3 days of treatment, in order to retain only those who had not relapsed during the first 72 hours (89 patients: 42 in group I; 47 in group II). As Holter monitoring was not available in all centres, follow-up was assessed by conventional ECG during clinical examination after 2 weeks, 6 weeks, 3 months and 6 months. The results seem to indicate that cibenzoline was more effective at the 6th month (20% recurrence rate in group I compared to 43.2% in group II). This difference was significant especially at the end of the 2nd week of treatment (p less than 0.04); the number of recurrences did not differ significantly between the two groups thereafter. In general the clinical tolerance was good. Biochemical tests showed a greater increase in serum transaminases (SGOT) in the cibenzoline than in the QAGS group but this difference did not attain statistical significance. We conclude that at 6 months cibenzoline is more effective than QAGS in preventing recurrent atrial fibrillation.
AuthorsY Frances, R Luccioni, M Delaage, G Donnarel, J L Medvedowsky, J C Quiret
JournalArchives des maladies du coeur et des vaisseaux (Arch Mal Coeur Vaiss) Vol. 78 Spec No Pg. 99-103 (Oct 1985) ISSN: 0003-9683 [Print] France
Vernacular TitlePrévention au long cours des récidives de fibrillation auriculaire par la cibenzoline. Etude multicentrique à propos de 89 observations.
PMID3938266 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Arrhythmia Agents
  • Imidazoles
  • cifenline
Topics
  • Adult
  • Aged
  • Anti-Arrhythmia Agents (therapeutic use)
  • Atrial Fibrillation (physiopathology, prevention & control)
  • Atrial Flutter (prevention & control)
  • Clinical Trials as Topic
  • Electrocardiography
  • Female
  • Humans
  • Imidazoles (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: